



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	361971	Eagle Clinical BIO-D
ARTG entry for	Medicine Listed	
Sponsor	Integria Healthcare Australia Pty Ltd	
Postal Address	PO Box 4854, EIGHT MILE PLAINS, QLD, 4113 Australia	
ARTG Start Date	14/04/2021	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Eagle Clinical BIO-D

Product Type	Single Medicine Product	Effective Date	14/04/2021
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Maintain/support general health and wellbeing
Maintain/support healthy teeth
Maintain/support teeth mineralisation
Maintain/support bone health
Maintain/support (state mineral) absorption in bones
Help maintain/support bone mineralisation
Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life
Maintain/support immune system health
Maintain/support healthy immune system function
Maintain/support muscle function
Maintain/support (state vitamin/mineral/nutrient) levels in the body
Maintain/support (state vitamin/mineral) within normal range

Indication Requirements

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Indication only for use for medicines that contain vitamin D as an active ingredient. The medicines may only contain a maximum recommended daily dose of 25 micrograms or less of vitamin D and as a minimum, also contain at least 25% of the RDI in the recommended daily dose of vitamin D.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to serious immunological diseases.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record



Australian Government
Department of Health
Therapeutic Goods Administration

Warnings

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet. The medicine should not be taken in combination with supplements containing Vitamin D without medical advice (or words to that effect). Use in children under 9 years is not recommended. Calcifediol may have similar effects to Vitamin D. Consult your health care professional before taking in combination with other medicines. If symptoms persist, seek the advice of a healthcare professional. For practitioner dispensing only.

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
-----------	-----------------

Components

1 . Formulation 1

Dosage Form Tablet, uncoated

Route of Administration Oral

Visual Identification

Active Ingredients

calcifediol monohydrate	.01 mg
-------------------------	--------

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate
croscarmellose sodium
crospovidone
dl-alpha-tocopherol
magnesium stearate
medium chain triglycerides
microcrystalline cellulose
silicon dioxide
sodium ascorbate
starch sodium octenyl succinate
sucrose

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary